UK

Patient receiving eye drops
#MHRA #Myopia #UK

MHRA approves myopia treatment for children in UK 

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea (low-dose atropine) to slow the progression of myopia in children.  The drug, developed by pharmaceutical company Santen, becomes the first licensed treatment to slow childhood myopia. The approval follows authorisation by the European Commission and the launch in… Read More

#News #Regulatory

MHRA
#MHRA #Rare disease #Rare diseases #UK

UK commits to major regulatory reform for rare therapies

The rulebook for rare disease therapies will be overhauled to make it quicker and easier to get these therapies tested, manufactured and approved in the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) has announced.  The announcement came in a new paper supporting the ambitions of the UK Government’s… Read More

#News #Regulatory

UK
#Clinical trial #National Institute for Health Research #UK

UK’s NIHR aims to bring commercial research into primary care 

The UK’s National Institute for Health and Care Research (NIHR) has announced plans to establish 14 centres to expand commercial research delivery and improve access to clinical trials.  As revealed in the announcement, NIHR has awarded more than £14 million ($19 million) to GP-led primary care organisations… Read More

#News

UK and US flags
#Artificial intelligence (AI) #Biotechnology #Drug discovery #UK #United States

What does the US-UK tech partnership mean for AI drug discovery?

The recent state visit to the UK by US President Trump was accompanied by the unveiling of a ‘US-UK tech partnership’ on 16 September. DDW speaks to experts at MHA’s life science team, who advise biotechnology and pharma firms in both the UK and US, on what this means for… Read More

#Exclusive Content

#AI #Innovation #UK

Lord Hague of Richmond opens new £1.2 billion UK innovation district

Lord Hague of Richmond, Chancellor of the University of Oxford, has opened a flagship £1.2 billion ($1.6 billion) global innovation district in Oxford in a boost to UK science, technology and AI sectors.  Oxford North, approximately one million square feet in size, is equipped with newly developed… Read More

#News

UK financial markets
#AstraZeneca #Drug development #Investment #UK

AstraZeneca halts £200m research investment in UK 

AstraZeneca has halted its planned £200 ($270) million investment in a research facility in Cambridge, UK, according to reports from Reuters.  The investment, which was anticipated to generate 1,000 new jobs, is currently on hold.  The pharmaceutical company's decision indicates that none of its newly announced funding, initially revealed in… Read More

#Business & Investment #News

Patient speaking to psychiatrist
#Clinical trials #Mental health #Psychiatry #UK

First NHS-embedded clinical trial site for mental health launches

The UK’s first fully NHS-embedded commercial research for brain and mental health conditions has been launched by Clerkenwell Health.   Developed in partnership with Rotherham Doncaster and South Humber (RDaSH) NHS Foundation Trust, the initiative aims to set a new standard for how trials are delivered in the… Read More

#News

MHRA
#Biogen #Clinical trials #Mental health #MHRA #Regulatory #UK

Treatment for post-natal depression authorised in UK

The first targeted treatment for post-natal depression (PND) has been authorised for use in the UK through the approval of Biogen’s zuranolone by the Medicines and Healthcare Products Regulatory Agency (MHRA). Biogen state that the marketing authorisation by the MHRA addresses a critical, unmet need in maternal health due to… Read More

#News

#Clinical trials #Drug discovery #National Institute for Health Research #UK

New network to boost industry clinical trials in the UK

The National Institute for Health and Care Research (NIHR) has awarded £6.5 (£8.7) million, funded jointly through a public-private partnership with the pharmaceutical industry, to establish a UK-wide Commercial Research Delivery Centre (CRDC) Network.   The new Network will provide strategic coordination of all 21 CRDCs across the… Read More

#News

UK
#Financing #Investment #Life sciences #Start-ups #UK

Growing investor interest in later-stage UK life science companies

New research into the UK life sciences landscape has revealed a growing trend of investment into more mature companies.   Pioneer Group’s ‘Life Science Start Up Report’ also highlights a persistent regional imbalance, with ‘Golden Triangle’ university spinouts attracting significantly more funding than those elsewhere.  Whilst the number of deals in… Read More

#Business & Investment #News #Start-up Zone

Cell and gene therapy
#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Manufacturing #MHRA #UK

Landmark UK legislation improves access to personalised therapies

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has brought in new regulations designed to make it easier for personalised cancer treatments and gene therapies to be made where patients are treated.  The new legislation ‘The Human Medicines (Amendment) (Modular Manufacture and Point of Care) Regulations… Read More

#News #Trending News

#Alzheimer's #Association of the British Pharmaceutical Industry #National Institute for Health and Care Excellence (NICE) #UK

From the Editor: Not NICE enough

The recent decision by the National Institute of Health and Care Excellence (NICE) to reject two Alzheimer’s drugs on the basis of “not providing good value for money” was met with considerable disappointment.  Pharmaceutical company Eisai, developer of the rejected therapy lecanemab, was understandably disappointed , saying it was “deeply… Read More

#Exclusive Content

#Biomanufacturing #Biopharma #Collaboration #UK

UK business and academia partner on innovative biopharma research

Twenty-three new Prosperity Partnerships will tackle key industry challenges in areas from drug manufacturing and artificial intelligence to cybersecurity. The UKRI Engineering and Physical Sciences Research Council (EPSRC) is funding the partnerships with a £41 ($55.7) million investment, matched with a further £56 ($76) million from businesses and academia.  Each… Read More

#Business & Investment #News

#Career #Drug development #Drug discovery #England #From the top #Golden Triangle #Interview #Medicines Discovery Catapult #Nanomedicine / nanotechnology #Northern Ireland #Scotland #UK #University of Oxford

New podcast: UK Spotlight: Innovation and discovery

This is the latest episode of the free DDW narrated podcast, titled “UK Spotlight: Innovation and discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Where is the drug discovery expertise happening in the UK?”, “From the top: Dr… Read More

#News

DNA sequencing
#Genetic diseases #Genetics / genomes #Rare diseases #SynaptixBio #UK #UK government

UK genetic screening plan welcomed by biotech

The UK Government has announced that every newborn baby in England will have their genetic code mapped to test for a wide range of conditions, part of a plan that will also see £650m invested in DNA research by 2030.  The Department for Health and Social Care… Read More

#News

#Association of the British Pharmaceutical Industry #Pharmaceutical industry #UK #UK government

UK doubles statutory payment rate on pharma sales

The UK government has doubled the rate that pharmaceutical companies repay on the sales of newer products to the NHS under the statutory scheme for branded medicines to a record 31%.  Following a consultation, the government has decided to raise the statutory scheme payment rate for newer branded medicines from… Read More

#Business & Investment #News